Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF

被引:136
作者
Emuss, V
Garnett, M
Mason, C
Marais, R
机构
[1] Inst Canc Res, Signal Transduct Team, Canc Res UK, Ctr Cell & Mol Biol, London SW3 6JB, England
[2] Wellcome Trust Sanger Inst, Hinxton, England
基金
英国惠康基金;
关键词
D O I
10.1158/0008-5472.CAN-05-1683
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The protein kinase B-RAF is mutated in similar to 8% of human cancers. Here we show that presumptive mutants of the closely related kinase, C-RAF, were detected in only 4 of 545 (0.7%) cancer cell lines. The activity of two of the mutated proteins is not significantly different from that of wild-type C-RAF and these variants may represent rare human polymorphisms. The basal and B-RAF-stimulated kinase activities of a third variant are unaltered but its activation by RAS is significantly reduced, suggesting that it may act in a dominant-negative manner to modulate pathway signaling. The fourth variant has elevated basal kinase activity and is hypersensitive to activation by RAS but does not transform mammalian cells. Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene. This lack of activation occurs because C-RAF lacks a constitutive charge within a motif in the kinase domain called the N-region. This fundamental difference in RAF isoform regulation explains why B-RAF is frequently mutated in cancer whereas C-RAF mutations are rare.
引用
收藏
页码:9719 / 9726
页数:8
相关论文
共 29 条
  • [1] Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade
    Avruch, J
    Khokhlatchev, A
    Kyriakis, JM
    Luo, ZJ
    Tzivion, G
    Vavvas, D
    Zhang, XF
    [J]. RECENT PROGRESS IN HORMONE RESEARCH, VOL 56, 2001, 56 : 127 - 155
  • [2] Mutations in conserved regions 1, 2, and 3 of Raf-1 that activate transforming activity
    Chan, EYW
    Stang, SL
    Bottorff, DA
    Stone, JC
    [J]. MOLECULAR CARCINOGENESIS, 2002, 33 (04) : 189 - 197
  • [3] Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
    Ciampi, R
    Knauf, JA
    Kerler, R
    Gandhi, M
    Zhu, ZW
    Nikiforova, MN
    Rabes, HM
    Fagin, JA
    Nikiforov, YE
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (01) : 94 - 101
  • [4] Mutations of the BRAF gene in human cancer
    Davies, H
    Bignell, GR
    Cox, C
    Stephens, P
    Edkins, S
    Clegg, S
    Teague, J
    Woffendin, H
    Garnett, MJ
    Bottomley, W
    Davis, N
    Dicks, N
    Ewing, R
    Floyd, Y
    Gray, K
    Hall, S
    Hawes, R
    Hughes, J
    Kosmidou, V
    Menzies, A
    Mould, C
    Parker, A
    Stevens, C
    Watt, S
    Hooper, S
    Wilson, R
    Jayatilake, H
    Gusterson, BA
    Cooper, C
    Shipley, J
    Hargrave, D
    Pritchard-Jones, K
    Maitland, N
    Chenevix-Trench, G
    Riggins, GJ
    Bigner, DD
    Palmieri, G
    Cossu, A
    Flanagan, A
    Nicholson, A
    Ho, JWC
    Leung, SY
    Yuen, ST
    Weber, BL
    Siegler, HF
    Darrow, TL
    Paterson, H
    Marais, R
    Marshall, CJ
    Wooster, R
    [J]. NATURE, 2002, 417 (6892) : 949 - 954
  • [5] CRITICAL TYROSINE RESIDUES REGULATE THE ENZYMATIC AND BIOLOGICAL-ACTIVITY OF RAF-1 KINASE
    FABIAN, JR
    DAAR, IO
    MORRISON, DK
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (11) : 7170 - 7179
  • [6] Guilty as charged: B-RAF is a human oncogene
    Garnett, MJ
    Marais, R
    [J]. CANCER CELL, 2004, 6 (04) : 313 - 319
  • [7] Houben Roland, 2004, J Carcinog, V3, P6, DOI 10.1186/1477-3163-3-6
  • [8] Ikenoue T, 2003, CANCER RES, V63, P8132
  • [9] Kerkhoff E, 1998, CANCER RES, V58, P1636
  • [10] Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
    Kolch, W
    [J]. BIOCHEMICAL JOURNAL, 2000, 351 : 289 - 305